Neuren Pharmaceuticals Limited   Report issue

For profit Phase 2
Founded: Camberwell Australia (1993)

Organization Overview

First Clinical Trial
2010
NCT00961779
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Neuren Pharmaceuticals Limited | Neuren Pharmaceuticals Ltd

Active Ingredients

Drugs in Phase 2 Trials (2)

nnz2566 (8 trials)

nnz-2591 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Concussion (Phase 2)

Brain Injuries (Phase 2)

Brain Injuries, Traumatic (Phase 2)

Fragile X Syndrome (Phase 2)

Rett Syndrome (Phase 2)

Syndrome (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 13
  • # of Trial APIs: 2